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Other than the influence of ionizing radiation and benign thyroid disease, little is known about the risk factors for differenti-
ated thyroid cancer (TC) which is an increasing common cancer worldwide. Consistent evidence shows that body mass is posi-
tively associated with TC risk. As excess weight is a state of chronic inflammation, we investigated the relationship between
concentrations of leptin, adiponectin, C-reactive protein, interleukin (IL)-6, IL-10 and tumor necrosis factor (TNF)-a and the risk
of TC. A case-control study was nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) study
and included 475 first primary incident TC cases (399 women and 76 men) and 1,016 matched cancer-free cohort participants.
Biomarkers were measured in serum samples using validated and highly sensitive commercially available immunoassays.
Odds ratios (ORs) of TC by levels of each biomarker were estimated using conditional logistic regression models, adjusting for
BMI and alcohol consumption. Adiponectin was inversely associated with TC risk among women (ORT3vs.T150.69, 95% CI:
0.49–0.98, Ptrend50.04) but not among men (ORT3vs.T151.36, 95% CI: 0.67–2.76, Ptrend50.37). Increasing levels of IL-10
were positively associated with TC risk in both genders and significantly so in women (ORT3vs.T151.59, 95% CI: 1.13–2.25,
Ptrend50.01) but not in men (ORT3vs.T151.78, 95% CI: 0.80–3.98, Ptrend50.17). Leptin, CRP, IL-6 and TNF-a were not associ-
ated with TC risk in either gender. These results indicate a positive association of TC risk with IL-10 and a negative associa-
tion with adiponectin that is probably restricted to women. Inflammation may play a role in TC in combination with or
independently of excess weight.
Introduction
In Western countries, thyroid cancer incidence has been
increasing over the last two decades thereby becoming the
second most commonly diagnosed cancer after breast cancer
in women younger than 45 years.1,2 The increase in the
search of thyroid nodules mainly through ultrasonography
has led to vast increases in differentiated thyroid cancers
(TC), the most common form of thyroid cancer that includes
papillary and follicular carcinomas.2 Exposure to ionizing
radiations and history of benign thyroid diseases are the only
What’s new?
How does being overweight lead to thyroid cancer? These authors investigated, using data from the EPIC cohort. Considering obe-
sity as a state of chronic inflammation, they looked at levels of various proteins associated with inflammation, including C-reactive
protein, IL-10, adiponectin, and others, and compared these with TC risk. Women with high adiponectin levels were less likely to
develop thyroid cancer, while those with high IL-10 levels had increased TC risk. No significant association was seen in men.
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relatively strong risk factors for TC though unlikely the rea-
son of the upward incidence trends.2–4 Other possible risk
factors are ill-understood. There is consistent evidence that
excess body weight and obesity are associated with a modest
increase in risk of TC,5–7 and the mechanisms underlying
this association may involve inﬂammation.8,9 Indeed, the adi-
pose tissue of overweight individuals is characterized by the
inﬁltration of macrophages resulting in chronic systemic
inﬂammation and in the release of cytokines and adipokines
into the circulation.10 Adipose tissue secretes hundreds of
adipokines of which the best studied are leptin and adiponec-
tin, which regulate important biological processes such as
appetite, insulin sensitivity, thermogenesis, fatty acid oxida-
tion and immune response.11 Adipokine secretion is altered
in adipose tissue dysfunction and may contribute to a spec-
trum of obesity-associated diseases.9
Both experimental and epidemiological data suggest that
local organ-speciﬁc inﬂammation plays a role in TC and
benign thyroid conditions. TC is often characterized by the
inﬁltration of inﬂammation-immune cells, and autoimmune
thyroid diseases, such as Hashimoto’s thyroiditis and Grave’s
disease, have been associated, in some studies, with an
increased risk of TC.12,13 Systemic inﬂammation, character-
ized by higher circulating levels of cytokines, has also been
observed in patients with Graves’ disease, hyperthyroidism
and toxic nodular goiter.14,15 Systemic inﬂammation has also
been associated with the development of several cancer types
and previous reports have shown that elevated levels of cyto-
kines and low levels of adiponectin were associated with an
increased risk of endometrial,16–18 breast,19 ovarian,20 liver21
and colon22 cancers.
Few retrospective case-control studies, mostly with very
small sample size (including between 20 and 163 subjects),
reported higher circulating levels of some cytokines (includ-
ing C-reactive protein [CRP], interleukin [IL]-6, IL-10, tumor
necrosis factor [TNF]-a) as well as leptin, among TC
cases.23–27 Conversely, circulating levels of adiponectin, an
adipokine that is inversely related to adiposity, were found to
be signiﬁcantly lower in 175 TC cases than in 107 controls.28
We have set up a study nested within the European Pro-
spective Investigation into Cancer and Nutrition (EPIC)
cohort to investigate the relationship between the risk of TC
and the prediagnostic concentrations of leptin, adiponectin,
CRP, IL-6, IL-10 and TNF-a. To our knowledge, this is the
ﬁrst prospective study investigating the association of pre-
diagnostic levels of adipokines and inﬂammation markers
with TC risk.
Methods
Study population and blood sample collection
The EPIC cohort is a large, multicenter prospective study,
designed to investigate the associations between nutritional,
lifestyle, metabolic and genetic risk factors and cancer. It was
initiated in 1992 in 10 European countries (Denmark, France,
Germany, Greece, Italy, the Netherlands, Norway, Spain,
Sweden and United Kingdom) and involved about 370,000
women and 150,000 men. Study population and baseline data
collection have previously been described in details.29 In
brief, questionnaires included data about diet, reproductive
history, use of exogenous hormones, tobacco smoking and
alcohol consumption, education level, occupational history,
physical activity and history of selected diseases. Anthropo-
metric variables were measured according to standardized
protocols.29
About 246,000 women and 140,000 men also provided a
blood sample, collected according to a standardized protocol
in France, Germany, Greece, Italy, the Netherlands, Norway,
Spain and the United Kingdom.29 From each subject, about
30 ml of blood were drawn, and serum (except in Norway),
plasma, erythrocytes and buffy coat were aliquoted in plastic
straws of 0.5 ml each, which were stored in liquid nitrogen
(–1968C) in a centralized biobank. In Denmark, blood frac-
tions were aliquoted into 1 ml tubes, and stored in the vapor
phase of liquid nitrogen containers (–1508C). In the Swedish
center of Umea, blood samples were divided into 10 aliquots
of 1.5 ml each (six plasma, two buffy coat and two erythro-
cytes), which were rapidly frozen at 2808C in standard
freezers.
All participants have given their consent to participate
into the EPIC study. The Internal Review Board of IARC
and local institutional review boards in participating centers
have approved the study.
Follow-up for cancer incidence and vital status
Incident cancer cases were identiﬁed through record linkage
with regional cancer registries in most countries and through
health insurance records, cancer and pathology registries and
active follow-up of study subjects in France, Germany and
Greece. Data on vital status were obtained from mortality
registries at the regional or national level, in combination
with data collected by active follow-up (Greece). For each
EPIC center, closure dates of the study period were deﬁned
as the latest dates of complete follow-up for both cancer inci-
dence and vital status (dates varied between centers, from
June 2008 to December 2013).
Selection of cases and controls
Case subjects were selected among participants who were
cancer-free (other than nonmelanoma skin cancer), had
donated blood at recruitment into the cohort and who were
diagnosed with TC between recruitment and the end of
follow-up. Cases were coded according to the 10th revision
of the WHO International Classiﬁcation of Disease (code
C73). This analysis focused on differentiated thyroid cancer,
i.e., papillary (morphologic codes: 8050, 8130, 8260, 8340–
8344 and 8350), follicular carcinomas (8290, 8330–8335) and
not otherwise speciﬁed, which are likely to also be papillary
(8000, 8010, 8140). Thyroid cancer cases with rare or missing
histological types (37 medullary, 9 anaplastic, 1 lymphoma, 4
other morphologies and 1 missing) were not included. A total
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of 475 incident TC cases were included (363 papillary, 84 fol-
licular and 28 not otherwise speciﬁed TC). Tumor-node-
metastasis (TNM) stage was known for 56.4% of the eligible
cases and used to group cancers into localized (T1) and more
advanced (T2) cancers.
For each case subject with TC, two control subjects for
women, and three for men were chosen at random among
appropriate risk sets consisting of all cohort members who
were alive and without a reported cancer diagnosis (except
nonmelanoma skin cancer) at the time of diagnosis of the
index case. Matching procedures have been described
before.30 In brief, matching variables included study recruit-
ment center, sex, age, date, time, fasting status at blood col-
lection and duration of follow-up (duration for the control
must be greater than for the index case). A total of 1,016
controls were selected for the study.
Laboratory measurements
Serum was used for laboratory assays except for samples
from Norway (citrated plasma) and Umea, Sweden (heparin
plasma). Leptin was measured by immunoradiometric assay
(IDS, Paris, France), while adiponectin and CRP were mea-
sured by enzyme-linked immunosorbent assays (R&D, United
Kingdom). IL-6, IL-10 and TNF-a were measured by a
highly sensitive multiplexing electrochemiluminescent
method (V-PLEXTM Custom Human Cytokine Kit, Meso
Scale Discovery, Rockville, MD).
All assays were performed at IARC by technicians who
were blind to case-control status of the subjects. Samples
from cases and matched controls were analyzed together,
within the same analytical batch. For quality control, three
plasma samples from nondiseased subjects were analyzed in
duplicate within each analytical batch. Mean intrabatch coef-
ﬁcients of variation, calculated on the concentrations from
the quality control samples, varied between 2.6% for CRP, to
9.9% for IL-10.
Of a total of 1,491 subjects, 5 had missing values for adi-
ponectin, 6 for CRP, 37 for leptin and 49 for IL-6, IL-10 and
TNF-a. These subjects were excluded from the analyses for
each particular biomarker. Twenty-seven values (1.8%) were
below the limit of quantiﬁcation (LOQ) for CRP, 75 (5%) for
IL-10 and 46 (3%) for IL-6. These values were set to the
LOQ: 78 pg/ml for CRP, 0.15 pg/ml for IL-10 and 0.16 pg/
ml for IL-6. No value was below the LOQ for leptin, adipo-
nectin or TNF-a.
Statistical analyses
Participant characteristics (means or percentages) were com-
pared between cases and controls within matched sets, for
men and women separately, using conditional logistic regres-
sion. Concentrations of the biomarkers were transformed log-
arithmically to approximate the normal distribution in all
parametric analyses.
Prediagnostic levels of inﬂammation markers among con-
trols were compared between men and women, using Mann-
Whitney-Wilcoxon test. Spearman’s partial correlation coefﬁ-
cients between inﬂammation markers and lifestyle factors
were calculated among controls, adjusting for age at blood
donation (continuous) and laboratory batch.
Odds ratios (ORs) and corresponding 95% conﬁdence
intervals (CIs) for TC in relation to sex-speciﬁc tertiles of
inﬂammation markers (based on the distribution of controls)
were estimated using logistic regression conditional on
matching factors (basic models), separately for men and
women. Tests for trends in ORs by tertiles were computed by
assigning consecutive scores to the tertiles.
The effects of potential confounders (additionally to the
matching criteria, controlled for by design) were examined
by including additional terms into the logistic regression
models. The following confounders were tested: smoking sta-
tus, duration of smoking, physical activity, alcohol consump-
tion, education level, age at menarche, parity, age at ﬁrst
FTP, number of FTP, breast feeding, menopausal status,
exogenous hormone use, anthropometric variables (height,
BMI, WC, HC and WHR). Only BMI and alcohol consump-
tion affected point estimates by >10% and were therefore
retained in the adjusted models.
For analyses of statistical heterogeneity by selected cofac-
tors, p-values for heterogeneity were derived by testing an
interaction term between the tertile score of inﬂammation
markers and the cofactor.
All statistical tests and corresponding p-values were two-
sided, and p-values <0.05 were considered statistically signiﬁ-
cant. All analyses were performed using the SAS software
package (Version 9.4, SAS Institute, Cary, NC).
Results
Baseline characteristics of the study population are described
in Table 1. Cases were diagnosed at a mean age of 58 years,
after an average follow-up time of about 8 years. Among
women, TC cases were signiﬁcantly taller, had a larger BMI
and waist circumference and a lower alcohol intake than con-
trols. The associations with height and alcohol intake but not
BMI and waist circumference, were in the same direction in
men as in women but no associations were signiﬁcant, possi-
bly due to the lower number of male than female cases.
Supporting Information Table 1 shows prediagnostic levels
of inﬂammation markers in controls by gender. Levels of lep-
tin and adiponectin were signiﬁcantly higher while TNF-a
levels were signiﬁcantly lower in women than in men. Levels
of CRP and other cytokines were similar in both genders.
Table 2 shows correlations between different inﬂammation
markers, age and anthropometric indexes. The strongest cor-
relations (0.49) were found between leptin and BMI and
waist circumference in both genders. Adiponectin was mod-
erately inversely correlated with BMI, waist circumference
and leptin but positively correlated with age (60.20). CRP,
IL-6 and TNF-a were also moderately correlated with BMI,
waist circumference and leptin and with each other. None of
C
an
ce
r
E
p
id
em
io
lo
g
y
Dossus et al. 1335
Int. J. Cancer: 142, 1332–1342 (2018) VC 2017 International Agency for Research on Cancer (IARC/WHO); licensed by UICC
the inﬂammation markers was substantially correlated with
IL-10 or height.
Table 3 presents the association between tertiles of inﬂam-
mation markers and TC risk, separately for women and men.
Among women, a statistically signiﬁcant inverse association
was observed in the basic model between TC risk and adipo-
nectin (ORT3vs.T15 0.67, 95% CI: 0.48–0.93, Ptrend5 0.02)
while IL-10 was positively associated (ORT3vs.T15 1.54, 95%
CI: 1.10–2.16, Ptrend5 0.02). Adjustment for TC risk factors
did not substantially modify these ﬁndings (ORT3vs.T15 0.69,
Table 1. Selected characteristics of the study population at blood collection by gender
Women Men
Cases Controls p-Value1 Cases Controls p-Value1
Number 399 791 – 76 225 –
Age at blood collection (years)2 50.2 (8.5) 50.2 (8.6) – 49.9 (8.9) 49.8 (8.7) –
Age at diagnosis (years)2 58.4 (8.6) – – 58.5 (9.5) – –
Years between blood collection
and cancer diagnosis2
8.2 (4.4) – – 8.6 (4.7) – –
Height (cm)2 161.3 (6.3) 160.2 (6.6) 0.002 176.5 (6.7) 175.3 (6.3) 0.14
Body mass index (kg/m2)2 26.1 (4.5) 25.5 (4.6) 0.02 26.4 (3.0) 26.4 (3.4) 0.87
Waist circumference (cm)2 81.9 (11.3) 80.3 (11.1) 0.01 94.6 (10.0) 94.5 (9.9) 0.95
Alcohol intake (g/day)2 6.1 (9.0) 7.5 (10.9) 0.02 17.5 (18.3) 19.5 (23.6) 0.48
Smoking status (%)3
Never smoker 60 60 0.96 32 35 0.77
Ex smoker 21 21 35 35
Current smoker 19 18 33 30
Education level (%)3
None or primary 42 41 0.83 30 30 0.99
Secondary or more 58 59 70 70
1From logistic regression conditional on matching factors.
2Mean and standard deviation.
3Percentage excluding participants with missing variables.
Table 2. Spearman correlation coefficients between prediagnostic levels of inflammation markers1 and age and anthropometric factors among
controls and corresponding p-values2 by gender
Age Alcohol intake BMI Waist circ. Height Leptin Adiponectin CRP IL-10 IL-6
Women
Leptin 0.11 20.12 0.64 0.59 20.10
Adiponectin 0.21 0.13 –0.18 –0.23 0.01 –0.22
CRP 0.17 20.07 0.41 0.39 20.08 0.36 –0.17
IL-10 0.01 20.02 0.08 0.07 20.04 0.07 20.01 0.13
IL-6 0.15 20.13 0.37 0.33 20.12 0.25 20.10 0.36 0.26
TNF-a 0.17 –0.15 0.26 0.25 –0.17 0.20 20.07 0.18 0.33 0.42
Men
Leptin 0.16 0.05 0.49 0.51 0.08
Adiponectin 0.23 0.03 20.21 20.18 0.12 0.02
CRP 0.09 0.06 0.24 0.18 20.10 0.26 20.17
IL-10 0.05 0.01 20.02 0.02 20.06 20.04 20.06 0.12
IL-6 0.24 0.03 0.12 0.15 0.08 0.23 20.15 0.48 0.21
TNF-a 0.01 20.03 0.05 0.03 0.01 0.00 20.19 0.17 0.44 0.38
CRP, C-reactive protein; IL, interleukin; TNF, tumor necrosis factor.
1Adjusted for laboratory batch and age at blood donation (when appropriate).
2p-Values <0.0001 in bold.
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Table 3. Odds ratio (OR) of differentiated TC by inflammation marker tertile in women and men
Women Men
P interaction
by genderTertiles1 Ptrend
2 Tertiles1 Ptrend
2
Leptin
(ng/ml)
<15.6 15.6–29.1 >529.1 <7.6 7.6–11.6 >511.6 0.79
Cases/
controls
113/250 147/250 128/249 26/73 25/73 24/72
OR [95% CI]:
basic
model3
1.00 1.30 [0.95; 1.77] 1.14 [0.81; 1.59] 0.47 1.00 0.94 [0.50; 1.79] 0.92 [0.47; 1.79] 0.80
OR [95% CI]:
adj.
model4
1.00 1.14 [0.82; 1.60] 0.87 [0.57; 1.31] 0.47 1.00 0.93 [0.48; 1.81] 0.93 [0.44; 1.95] 0.84
Adiponectin
(ng/ml)
<7,654.9 7,654.9–12,441.9 >512,441.9 <4,259.7 4,259.7–6257.8 >56,257.8 0.07
Cases/
controls
155/262 130/262 111/261 23/75 23/75 30/75
OR [95% CI]:
basic
model3
1.00 0.79 [0.58; 1.07] 0.67 [0.48; 0.93] 0.02 1.00 1.01 [0.51; 2.01] 1.35 [0.67; 2.72] 0.38
OR [95% CI]:
adj.
model4
1.00 0.84 [0.61; 1.14] 0.69 [0.49; 0.98] 0.04 1.00 1.02 [0.51; 2.04] 1.36 [0.67; 2.76] 0.37
C-reactive
protein
(ng/ml)
<722.1 722.1–1,887.8 >51,887.8 <754.7 754.7–2,055.5 >52,055.5 0.34
Cases/
controls
135/262 121/261 140/261 28/75 29/75 19/74
OR [95% CI]:
basic
model3
1.00 0.88 [0.65; 1.20] 1.05 [0.77; 1.41] 0.77 1.00 1.01 [0.54; 1.92] 0.68 [0.35; 1.34] 0.26
OR [95% CI]:
adj.
model4
1.00 0.85 [0.62; 1.17] 0.94 [0.68; 1.30] 0.70 1.00 1.02 [0.53; 1.95] 0.68 [0.34; 1.36] 0.27
IL-10
(pg/ml)
<0.22 0.22–0.31 >50.31 <0.22 0.22–0.32 >50.32 0.82
Cases/
controls
93/251 155/251 137/251 20/74 27/74 29/74
OR [95% CI]:
basic
model3
1.00 1.69 [1.23; 2.32] 1.54 [1.10; 2.16] 0.02 1.00 1.61 [0.75; 3.46] 1.81 [0.81; 4.02] 0.17
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Table 3. Odds ratio (OR) of differentiated TC by inflammation marker tertile in women and men (Continued)
Women Men
P interaction
by genderTertiles1 Ptrend
2 Tertiles1 Ptrend
2
OR [95% CI]:
adj.
model4
1.00 1.67 [1.21; 2.30] 1.59 [1.13; 2.25] 0.01 1.00 1.59 [0.74; 3.43] 1.78 [0.80; 3.98] 0.19
IL-6 (pg/ml) <0.34 0.34–0.53 >50.53 <0.32 0.32–0.58 >50.58 0.31
Cases/
controls
110/251 131/251 144/251 19/74 41/74 16/74
OR [95% CI]:
basic
model3
1.00 1.23 [0.89; 1.68] 1.38 [0.99; 1.94] 0.06 1.00 2.11 [1.10; 4.06] 0.85 [0.39; 1.85] 0.67
OR [95% CI]:
adj.
model4
1.00 1.20 [0.87; 1.66] 1.26 [0.88; 1.80] 0.21 1.00 2.09 [1.09; 4.03] 0.84 [0.39; 1.85] 0.68
TNF-a (pg/
ml)
<1.52 1.52–1.95 >51.95 <1.63 1.63–2.04 >52.04 0.53
Cases/
controls
125/252 121/251 138/251 26/74 27/74 23/74
OR [95% CI]:
basic
model3
1.00 1.00 [0.72; 1.38] 1.17 [0.83; 1.64] 0.39 1.00 1.02 [0.53; 1.97] 0.87 [0.41; 1.85] 0.73
OR [95% CI]:
adj.
model4
1.00 0.95 [0.68; 1.32] 1.08 [0.76; 1.53] 0.66 1.00 1.01 [0.52; 1.95] 0.86 [0.40; 1.84] 0.71
1Tertiles based on the gender-specific distribution of controls.
2Ptrend values were computed by assigning consecutive scores (scores of 1–3) to the categories.
3Logistic regression conditional on matching factors.
4Logistic regression conditional on matching factors and adjusted for BMI, and alcohol consumption.
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95% CI: 0.49–0.98, Ptrend5 0.04 for adiponectin, and
ORT3vs.T15 1.59, 95% CI: 1.13–2.25, Ptrend5 0.01 for IL-10).
None of the markers were signiﬁcantly associated with TC
risk among men (Ptrend 0.17) but the positive association
with IL-10 was similar to the one seen among women
(ORT3vs.T15 1.81, 95% CI: 0.81–4.02 in the basic model;
ORT3vs.T15 1.78, 95% CI: 0.80–3.98 in the adjusted model).
Similar results were observed when analyses were restricted
to papillary TC (Supporting Information Table 2). When
genders were combined, the negative association with
adiponectin was no longer signiﬁcant (ORT3vs.T15 0.79, 95%
CI: 0.58–1.07, Ptrend5 0.13), whereas a positive signiﬁcant
association with IL-10 was conﬁrmed (ORT3vs.T15 1.61,
95% CI: 1.18–2.21, Ptrend5 0.005) (Supporting Information
Table 3).
No statistically signiﬁcant heterogeneity was observed in
the inverse association between adiponectin and TC risk in
women by age at blood collection, national TC incidence,
education, smoking, BMI, waist circumference, menopausal
status, histologic type, TNM stage (Fig. 1) and country (data
not shown). The negative association with adiponectin was,
however, absent among women in whom the interval
between blood collection and TC diagnosis was <6 years
(OR: 1.07, 95% CI: 0.81–1.43).
Finally, we explored the effect of adiponectin (middle and
highest tertile vs. lowest tertile) according to BMI (<25 or
25; data not shown). The OR was 0.96 (95% CI: 0.62–1.46)
among normal-weight women and 0.66 (95% CI: 0.46–0.95)
among overweight and obese women. Although, therefore,
the negative association of high adiponectin level with TC
Figure 1. Odds ratios of differentiated TC for an increase in one tertile of adiponectin among women, stratified by selected variables.
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risk was only signiﬁcant the heaviest women the 95% CI of
the two ORs broadly overlap. Figure 2 (which includes both
women and men) shows lack of signiﬁcant heterogeneity in
the positive association of TC risk with IL-10 by the same
variables as in Figure 1 and country (data not shown).
Discussion
We showed for the ﬁrst time in a prospective study that high
adiponectin levels were associated with a lower risk of TC
among women while elevated IL-10 levels were associated
with an increased risk of TC probably in both genders. Lep-
tin, CRP, IL-6 and TNF-a were not associated with TC risk
in either gender.
Our results on adiponectin are consistent with the inverse
association observed with papillary TC in a previous case-
control study.28 Although Mitsiades et al.28 did not present
data for women only, 90% of the 175 TC cases included were
women. The lack of signiﬁcant association with adiponectin
in men, who were a minority also in our study, may be due
to chance or may suggest that the association may be more
relevant in women, as possibly suggested by the substantially
higher adiponectin levels compared to men. Prospective stud-
ies have shown a negative association of adiponectin levels
with the risk of women’s cancers related to weight excess
such as postmenopausal breast and endometrial can-
cers.18,31–33 A recent metaanalysis of 107 studies34 showed
however a negative association of adiponectin with a broad
range of cancers, including gastrointestinal and prostate can-
cers, in both case-control and prospective studies.
Several experimental in vivo and in vitro studies also
reported the expression of adiponectin receptors on thyroid
cancer cells and tissue.28,35 Adiponectin is an adipokine with
Figure 2. Odds ratios of differentiated TC for an increase in one tertile of IL-10, stratified by selected variables.
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antiinﬂammatory, and also antidiabetic, antiatherogenic and
antiangiogenic properties.36–38 The mechanisms by which
adiponectin may act on thyroid cancer still remain to be
identiﬁed but may include a protection against the develop-
ment of insulin resistance,39 in particular through the activa-
tion of the adenosine monophosphate kinase (AMPK)
pathway.35,40,41 Adiponectin has also been shown to directly
inhibit angiogenesis and promote apoptosis in vivo, through
the activation of the caspase cascade.42 Adiponectin has been
proposed as a possible mediator in the association between
BMI and cancer risk.31 Alternative pathways that may medi-
ate the BMI-TC association include hyperinsulinemia, meta-
bolic syndrome, insulin-like growth factors or sex steroids.9
In our study, adiponectin was inversely correlated with
BMI and waist circumference in both genders, but the nega-
tive association with TC risk was only signiﬁcant in women
with BMI 25. However, the 95% CIs of the ORs in women
whose BMI was <25 or 25 broadly overlapped. We cannot
therefore draw conclusions on whether adiponectin plays a
role in TC in addition to or independently of excess weight.
A number of relatively small studies have compared levels of
leptin, circulating cytokines, including IL-1b, IL-5, IL-6, IL-7,
IL-8, IL-9, IL-10, IL-13, TNF-a, IFN-g and CRP, among TC
cases and controls but results were not consistent across
studies.23–25,27,43–45 In prediagnostic samples, we observed no
signiﬁcant associations with leptin, CRP, IL-6 and TNF-a.
Only IL-10 was associated with an increased risk of TC con-
sistently in women and men, although the association was
statistically signiﬁcant only in women.
Three case-control studies (N< 23 TC cases) examined
the association between circulating levels of IL-10 and TC
risk.24,44,45 Only one of them reported signiﬁcantly higher IL-
10 levels among cases than among healthy controls.24 In
addition, two out of three other case-control studies observed
a signiﬁcant difference between TC cases and controls in IL-
10–1082 G/A (rs1800896), a genetic polymorphism associated
with an increase in the production of IL-10.46–48 In vitro
studies have shown that autocrine production of IL-10 might
favour thyroid cancer cell survival and proliferation49 and
higher IL-10 levels have been observed in patients with per-
sistent/recurrent disease.50 IL-10 is an antiinﬂammatory cyto-
kine characteristic of Th2 immunity and might therefore
counteract Th1 immune response and favour the escape of
tumor cells from immune destruction.51 IL-10 has been
shown to favour the progression and metastasis of several
tumors,51 while inconsistent effects have been observed on
the proliferation of breast tumor cells.52,53
The main strength of our study includes its large sample
size and its prospective design. As circulating levels of
inﬂammation markers might be affected by the presence of
the tumor, as well by diagnostic and therapeutic procedures,
pre-diagnostic concentrations are essential when examining
the etiologic role of inﬂammation in TC development to
avoid reverse causation bias. Our study has also limitations,
particularly the fact that we only measured inﬂammation
markers at one point in time. However, most inﬂammation
markers have shown good reproducibility in samples col-
lected at different time points.54 Repeated measurements of
inﬂammation markers and/or anthropometry and more in-
depth assessment of fat distribution would nevertheless
improve the classiﬁcation of individuals and therefore lead to
stronger associations with TC risk. The limited sample size in
men that reﬂects however the epidemiology of TC limit the
interpretation of the results in this group. In addition,
although information was available on histological subtypes
of TC, EPIC data did not include history of benign thyroid
diseases, thyroidectomy among control subjects and use of
drugs that could interfere with thyroid function. Likewise,
individual information on iodine deﬁciency and past expo-
sure to ionizing radiations have not been collected but we
know that severe iodine deﬁciency is rare in EPIC countries
and that exposure to ionizing radiation due to previous can-
cer treatment is unlikely because we excluded prevalent can-
cer cases other than nonmelanoma skin cancers. Finally, as
the increase in incidence observed over the last decades in
differentiated thyroid carcinomas is largely driven by changes
in diagnostic practices,2 an additional limitation is that we do
not have any indication on how the cancers have been
diagnosed.
In conclusion, our results suggest a possible negative asso-
ciation of TC risk with prediagnostic circulating levels of adi-
ponectin in women and an overall positive association with
those of IL-10. Longer follow-up in EPIC or the combination
of EPIC data with additional cohort studies are necessary to
understand whether adiponectin and, possibly, other inﬂam-
mation markers play a role in TC risk in combination with
or independently of excess weight.
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